Six things to know:
1. Overall revenue was about the same as the first quarter of 2022. Total sales were $106.4 million, a 1 percent increase year over year, according to a news release.
2. The spinal implants segment saw the largest year-over-year increase, at 3.6 percent. Spinal implant sales were $26.6 million.
3. Biologics sales rose 2.9 percent with $14.1 million.
4. The only segment that saw a decrease in quarterly sales was bone growth therapies, at $41.9 million, a 2.3 percent dip year over year.
5. Global orthopedic sales of $23.8 million represented a 2.2 percent increase year over year. Global spine sales remained about the same as the same period last year with a 0.4 percent increase.
6. Highlights of Orthofix’s first quarter included an FDA grant for the AccelStim bone growth stimulator and FDA clearance for the TrueLok EVO ring fixation system.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.